4.5 Article

Pattern of follow-up care and early relapse detection in breast cancer patients

Journal

BREAST CANCER RESEARCH AND TREATMENT
Volume 136, Issue 3, Pages 859-868

Publisher

SPRINGER
DOI: 10.1007/s10549-012-2297-9

Keywords

Breast cancer; Mammography; Physical examination; Relapse; Routine follow-up

Categories

Funding

  1. Dutch Cancer Society [KUN 2008-4086]

Ask authors/readers for more resources

Routine breast cancer follow-up aims at detecting second primary breast cancers and loco regional recurrences preclinically. We studied breast cancer follow-up practice and mode of relapse detection during the first 5 years of follow-up to determine the efficiency of the follow-up schedule. The Netherlands Cancer Registry provided data of 6,509 women, operated for invasive non-metastatic breast cancer in 2003-2004. In a random sample including 144 patients, adherence to follow-up guideline recommendations was studied. Mode of relapse detection was studied in 124 patients with a second primary breast cancer and 160 patients with a loco regional recurrence. On average 13 visits were performed during the first 5 years of the follow-up, whereas nine were recommended. With one, two and three medical disciplines involved, the number of visits was 9, 14 and 18, respectively. Seventy-five percent (93/124) of patients with a second primary breast cancer, 42 % (31/74) of patients with a loco regional recurrence after breast conserving surgery and 28 % (24/86) of patients with a loco regional recurrence after mastectomy had no symptoms at detection. To detect one loco regional recurrence or second primary breast cancer preclinically, 1,349 physical examinations versus 262 mammography and/or MRI tests were performed. Follow-up provided by only one discipline may decrease the number of unnecessary follow-up visits. Breast imaging plays a major and physical examination a minor role in the early detection of second primary breast cancers and loco regional recurrences. The yield of physical examination to detect relapses early is low and should therefore be minimised.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Computer Science, Artificial Intelligence

Using Explainable Machine Learning to Explore the Impact of Synoptic Reporting on Prostate Cancer

Femke M. Janssen, Katja K. H. Aben, Berdine L. Heesterman, Quirinus J. M. Voorham, Paul A. Seegers, Arturo Moncada-Torres

Summary: In this paper, the authors demonstrate the practical application of explainable machine learning (XML) in oncology, specifically in the study of the impact of synoptic reporting on prostate cancer patient survival. A comparison of two predictive models revealed that the XML model outperformed the traditional model, and the authors used SHAP values to explain the contribution of different features to the models' output.

ALGORITHMS (2022)

Meeting Abstract Oncology

Contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: Whart do they mean?

Kristien Keymeulen, Sandra Geurts, Loes Kooreman, Lucien Duijm, Sanne Engelen, Sigrid Vanwetswinkel, Ernest Luiten, Sabine Siesling, Adri Voogd, Vivianne Tjan-Heijnen

CANCER RESEARCH (2022)

Correction Biochemistry & Molecular Biology

Polygenic risk modeling for prediction of epithelial ovarian cancer risk (vol 30, pg 349, 2021)

Eileen O. Dareng, Jonathan P. Tyrer, Daniel R. Barnes, Michelle R. Jones, Xin Yang, Katja K. H. Aben, Muriel A. Adank, Simona Agata, Irene L. Andrulis, Hoda Anton-Culver, Natalia N. Antonenkova, Gerasimos Aravantinos, Banu K. Arun, Annelie Augustinsson, Judith Balmana, Elisa V. Bandera, Rosa B. Barkardottir, Daniel Barrowdale, Matthias W. Beckmann, Alicia Beeghly-Fadiel, Javier Benitez, Marina Bermisheva, Marcus Q. Bernardini, Line Bjorge, Amanda Black, Natalia V. Bogdanova, Bernardo Bonanni, Ake Borg, James D. Brenton, Agnieszka Budzilowska, Ralf Butzow, Saundra S. Buys, Hui Cai, Maria A. Caligo, Ian Campbell, Rikki Cannioto, Hayley Cassingham, Jenny Chang-Claude, Stephen J. Chanock, Kexin Chen, Yoke-Eng Chiew, Wendy K. Chung, Kathleen B. M. Claes, Sarah Colonna, Linda S. Cook, Fergus J. Couch, Mary B. Daly, Fanny Dao, Eleanor Davies, Miguel de la Hoya, Robin de Putter, Joe Dennis, Allison DePersia, Peter Devilee, Orland Diez, Yuan Chun Ding, Jennifer A. Doherty, Susan M. Domchek, Thilo Dork, Andreas du Bois, Matthias Durst, Diana M. Eccles, Heather A. Eliassen, Christoph Engel, Gareth D. Evans, Peter A. Fasching, James M. Flanagan, Renee T. Fortner, Eva Machackova, Eitan Friedman, Patricia A. Ganz, Judy Garber, Francesca Gensini, Graham G. Giles, Gord Glendon, Andrew K. Godwin, Marc T. Goodman, Mark H. Greene, Jacek Gronwald, Eric Hahnen, Christopher A. Haiman, Niclas Hakansson, Ute Hamann, Thomas V. O. Hansen, Holly R. Harris, Mikael Hartman, Florian Heitz, Michelle A. T. Hildebrandt, Estrid Hogdall, Claus K. Hogdall, John L. Hopper, Ruea-Yea Huang, Chad Huff, Peter J. Hulick, David G. Huntsman, Evgeny N. Imyanitov, Claudine Isaacs, Anna Jakubowska, Paul A. James, Ramunas Janavicius, Allan Jensen, Oskar Th. Johannsson, Esther M. John, Michael E. Jones, Daehee Kang, Beth Y. Karlan, Anthony Karnezis, Linda E. Kelemen, Elza Khusnutdinova, Lambertus A. Kiemeney, Byoung-Gie Kim, Susanne K. Kjaer, Ian Komenaka, Jolanta Kupryjanczyk, Allison W. Kurian, Ava Kwong, Diether Lambrechts, Melissa C. Larson, Conxi Lazaro, Nhu D. Le, Goska Leslie, Jenny Lester, Fabienne Lesueur, Douglas A. Levine, Lian Li, Jingmei Li, Jennifer T. Loud, Karen H. Lu, Jan Lubinski, Phuong L. Mai, Siranoush Manoukian, Jeffrey R. Marks, Rayna Kim Matsuno, Keitaro Matsuo, Taymaa May, Lesley McGuffog, John R. McLaughlin, Iain A. McNeish, Noura Mebirouk, Usha Menon, Austin Miller, Roger L. Milne, Albina Minlikeeva, Francesmary Modugno, Marco Montagna, Kirsten B. Moysich, Elizabeth Munro, Katherine L. Nathanson, Susan L. Neuhausen, Heli Nevanlinna, Joanne Ngeow Yuen Yie, Henriette Roed Nielsen, Finn C. Nielsen, Liene Nikitina-Zake, Kunle Odunsi, Kenneth Offit, Edith Olah, Siel Olbrecht, Olufunmilayo I. Olopade, Sara H. Olson, Hakan Olsson, Ana Osorio, Laura Papi, Sue K. Park, Michael T. Parsons, Harsha Pathak, Inge Sokilde Pedersen, Ana Peixoto, Tanja Pejovic, Pedro Perez-Segura, Jennifer B. Permuth, Beth Peshkin, Paolo Peterlongo, Anna Piskorz, Darya Prokofyeva, Paolo Radice, Johanna Rantala, Marjorie J. Riggan, Harvey A. Risch, Cristina Rodriguez-Antona, Eric Ross, Mary Anne Rossing, Ingo Runnebaum, Dale P. Sandler, Marta Santamarina, Penny Soucy, Rita K. Schmutzler, V. Wendy Setiawan, Kang Shan, Weiva Sieh, Jacques Simard, Christian F. Singer, Anna P. Sokolenko, Honglin Song, Melissa C. Southey, Helen Steed, Dominique Stoppa-Lyonnet, Rebecca Sutphen, Anthony J. Swerdlow, Yen Yen Tan, Manuel R. Teixeira, Soo Hwang Teo, Kathryn L. Terry, Mary Beth Terry, Mads Thomassen, Pamela J. Thompson, Liv Cecilie Vestrheim Thomsen, Darcy L. Thull, Marc Tischkowitz, Linda Titus, Amanda E. Toland, Diana Torres, Britton Trabert, Ruth Travis, Nadine Tung, Shelley S. Tworoger, Ellen Valen, Anne M. van Altena, Annemieke H. van der Hout, Els Van Nieuwenhuysen, Elizabeth J. van Rensburg, Ana Vega, Digna Velez Edwards, Robert A. Vierkant, Frances Wang, Barbara Wappenschmidt, Penelope M. Webb, Clarice R. Weinberg, Jeffrey N. Weitzel, Nicolas Wentzensen, Emily White, Alice S. Whittemore, Stacey J. Winham, Alicja Wolk, Yin-Ling Woo, Anna H. Wu, Li Yan, Drakoulis Yannoukakos, Katia M. Zavaglia, Wei Zheng, Argyrios Ziogas, Kristin K. Zorn, Zdenek Kleibl, Douglas Easton, Kate Lawrenson, Anna DeFazio, Thomas A. Sellers, Susan J. Ramus, Celeste L. Pearce, Alvaro N. Monteiro, Julie M. Cunningham, Ellen L. Goode, Joellen M. Schildkraut, Andrew Berchuck, Georgia Chenevix-Trench, Simon A. Gayther, Antonis C. Antoniou, Paul D. P. Pharoah

EUROPEAN JOURNAL OF HUMAN GENETICS (2022)

Correction Oncology

Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study (vol 38, pg 735.e17, 2020)

R. W. M. Vernooij, R. G. H. M. Cremers, H. Jansen, D. M. Somford, L. A. Kiemeney, G. van Andel, B. P. Wijsman, M. B. . Busstra, R. J. A. van Moorselaar, E. M. Wijnen, F. J. Pos, M. C. C. M. Hulshof, P. Hamberg, F. van den Berkmortel, C. A. Hulsbergen-van de Kaa, G. J. L. H. van Leenders, J. J. Fu, I. M. van Oort, K. K. H. Aben

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

Article Urology & Nephrology

The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer

Janneke E. W. Walraven, Theodora M. Ripping, Jorg R. Oddens, Bas W. G. van Rhijn, Catharina A. Goossens-Laan, Maarten C. C. M. Hulshof, Lambertus A. Kiemeney, J. A. Witjes, Valery E. P. P. Lemmens, Jacobus J. M. van der Hoeven, Ingrid M. E. Desar, Katja K. H. Aben, Rob H. A. Verhoeven

Summary: This study investigated the role of specialised genitourinary multidisciplinary team meetings (MDTMs) in decision-making and identified factors that influenced the probability of receiving treatment with curative intent for patients with muscle invasive bladder cancer (MIBC). The study found that age, performance status, and the type of hospital were associated with the likelihood of being discussed in an MDTM and receiving curative treatment. Patient preference was the main reason for non-adherence to treatment advice.

BJU INTERNATIONAL (2023)

Article Pathology

Interlaboratory Gleason grading variation affects treatment: a Dutch historic cohort study in 30 509 patients with prostate cancer

Rachel N. Flach, Carmen van Dooijeweert, Katja K. H. Aben, Britt B. M. Suelmann, Peter-Paul M. Willemse, Paul J. van Diest, Richard P. Meijer

Summary: There is substantial variation in Gleason grading of prostate cancer between Dutch pathology laboratories, which has an impact on treatment strategies. Lower grading laboratories tend to perform active treatment (AT) less often, while higher grading laboratories tend to perform AT more often. Lower grading laboratories also perform pelvic lymph node dissection (PLND) less frequently.

JOURNAL OF CLINICAL PATHOLOGY (2023)

Article Oncology

Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice

S. G. Creemers, B. Van Santvoort, F. W. P. J. van den Berkmortel, L. A. Kiemeney, I. M. van Oort, K. K. H. Aben, P. Hamberg

Summary: Participation in multidisciplinary team meetings is associated with a higher likelihood of receiving chemohormonal therapy in patients with metastatic prostate cancer, suggesting that the organizational structure of MDTs aids in the implementation of innovative treatment options.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

Meeting Abstract Oncology

Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial

V. C. G. Tjan-Heijnen, S. W. M. Lammers, S. M. E. Geurts, I. J. H. Vriens, A. C. P. Swinkels, C. H. Smorenburg, M. van der Sangen, J. R. Kroep, H. de Graaf, A. H. Honkoop, F. L. G. Erdkamp, W. K. de Roos, S. C. Linn, A. L. T. Imholz

ANNALS OF ONCOLOGY (2022)

Article Oncology

Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry

Gijs P. A. van den Bergh, Malou C. P. Kuppen, Hans M. Westgeest, Niven Mehra, Winald R. Gerritsen, Katja K. H. Aben, Inge M. van Oort, Reindert J. A. van Moorselaar, Diederik M. Somford, Alfonsus J. M. van den Eertwegh, Andre M. Bergman, Alphonsus C. M. van den Bergh, Carin A. Uyl-de Groot

Summary: This real-world population study investigates the incidence and treatment of visceral metastases (VMs) in castration-resistant prostate cancer (CRPC) patients and their survival. The study found that the location of VMs impacts patients' survival and despite an increase in radiological staging, many patients were not screened for VMs at the start of systemic treatment. Routine staging of CRPC patients is necessary.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

Article Oncology

Impact of Advanced External Beam Radiotherapy on Second Haematological Cancer Risk in Prostate Cancer Survivors

M. -c. Jahreiss, W. D. Heemsbergen, C. Janus, M. van de Pol, M. Dirkx, A. G. Dinmohamed, R. A. Nout, M. Hoogeman, L. Incrocci, K. K. H. Aben

Summary: This study examined the risk of second haematological cancer (SHC) after external beam radiotherapy (EBRT) for prostate cancer (PCa) in the Netherlands. The findings showed an increased risk of SHC in PCa patients who underwent EBRT, especially in the era of two-dimensional radiotherapy (2D-RT). The risk was significantly higher compared to active surveillance, but not compared to radical prostatectomy. These findings highlight the importance of further evaluating and improving EBRT techniques.

CLINICAL ONCOLOGY (2023)

Article Oncology

Longitudinal associations of adherence to lifestyle recommendations and health-related quality of life in patients with non-muscle invasive bladder cancer

Nikoletta Vidra, Ivy Beeren, Moniek van Zutphen, Katja K. Aben, Ellen Kampman, J. Alfred Witjes, Antoine G. van Der Heijden, Lambertus A. Kiemeney, Alina Vrieling

Summary: Although the evidence is limited, adherence to the WCRF/AICR lifestyle recommendations is associated with improved health-related quality of life in patients with NMIBC.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Clinical value of contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: a population-based cohort study

Kristien B. I. M. Keymeulen, Sandra M. E. Geurts, Loes F. S. Kooreman, Lucien E. M. Duijm, Sanne Engelen, Sigrid Vanwetswinkel, Ernest Luiten, Sabine Siesling, Adri C. Voogd, Vivianne C. G. Tjan-Heijnen

Summary: Breast MRI at primary DCIS diagnosis can detect additional synchronous cDCIS and cIBC, and is associated with a higher rate of metachronous cDCIS without decreasing the rate of metachronous cIBC. This finding is most evident in younger patients.

EUROPEAN RADIOLOGY (2023)

Meeting Abstract Urology & Nephrology

A nationwide study on the added value of (neo)adjuvant ADT in addition to modern dose-escalated external beam radiotherapy in men with high-risk localized prostate cancer

B. L. Heesterman, K. K. H. Aben, C. G. J. Van Straten, J. R. N. Van der Voort Van Zyp, L. P. Bokhorst

EUROPEAN UROLOGY (2022)

Meeting Abstract Oncology

Machine learning-based models for prediction of erectile dysfunction in localized prostate cancer

H. Hasannejadasl, C. Roumen, H. van der Poel, B. Vanneste, J. van Roermund, K. Aben, P. Kalendralis, B. Osong, L. Kiemeney, I. van Oort, R. Verwey, L. Hochstenbach, E. J. Bloemen-van Gurp, A. Dekker, R. Fijten

RADIOTHERAPY AND ONCOLOGY (2022)

Meeting Abstract Oncology

Characteristics of modern EBRT and its association with second primary cancer incidence

M. Jahreiss, K. Aben, M. Hoogeman, M. Dirkx, F. Pos, T. Janssen, A. Dekker, B. Vanneste, A. Minken, C. Hoekstra, R. J. Smeenk, L. Incrocci, W. Heemsbergen

RADIOTHERAPY AND ONCOLOGY (2022)

No Data Available